Spotlight on pioglitazone in type 2 diabetes mellitus

Treatments in Endocrinology

Volumn 5, Issue 3, 2006, Pages 189-191

  Waugh, John ^a   Keating, Gillian M ^a   Plosker, Greg L ^a   Easthope, Stephanie ^a   Robinson, Dean M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ARTERIOSCLEROSIS; ARTHRALGIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EDEMA; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HEADACHE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; GLUCOSE BLOOD LEVEL; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RISK FACTORS;

EID: 33646535908     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605030-00006     Document Type: Review

References (45)

1. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome-proliferator- activated receptor γ (PPARγ). J Biol Chem 1995; 270 (22): 12953-6
2. Takeda Pharmaceuticals America Inc. Actos (pioglitazone hydrochloride) tablets prescribing information [online]. Available from URL: http://www.actos.com/ [Accessed 2005 Dec 19]
3. Yki-J̈arvinen H. Thiazolidinediones. N Engl J Med 2004 Sep 9; 351 (11): 1106-18
4. Diani AR, Sawada G, Wyse B, et al. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004 Jan; 286 (1): E116-22
5. Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus. Drugs 2005; 65 (1): 1-13
6. de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001 Aug; 50 (8): 1863-71
7. Hu E, Tontonez P, Spiegelman BM. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα. Proc Natl Acad Sci USA 1995 Oct; 92: 9856-60
8. Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997 Sep; 46: 1393-9
9. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998 Mar; 101 (6): 1354-61
10. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001 Jul; 86 (7): 3452-6
11. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003 Sep; 26 (9): 2493-9
12. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003 Apr; 88 (4): 1637-45
13. Göke B. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002; 1 (5): 329-36
14. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108 Suppl. 2: S234-42
15. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 Nov; 23 (11): 1605-11
16. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003 Apr; 25 (4): 1074-95
17. Kaneko T, Baba S, Toyota T, et al. Clinical evaluation of an insulin-resistance improver, AD-4833, in NIDDM patients treated with diet alone: a placebo-controlled, double-blind, comparative study [in Japanese]. Rinsho Kenkyo 1997 Jun; 74 (5): 1491-509
18. Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001 Aug; 12 (5): 413-23
19. Scherbaum WA, Göke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002 Oct; 34 (10): 589-95
20. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004 Dec; 89 (12): 6068-76
21. Lübben G, Fennenkötter U, Weidenhammer J, et al. The COMPACT-study®: pioglitazone vs insulin for treatment of patients with type 2 diabetes mellitus: a medical and pharmacoeconomic analysis [abstract no. PDB9 plus poster]. 6th Annual International Society for Pharmacoeconomics and Outcomes Research European Congress; 2003 Nov 9-11; Barcelona
22. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7 (3): 162-9
23. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 Jul; 28 (7): 1547-54
24. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002 Apr; 25 (4): 708-11
25. Charbonnel BH, Matthews DR, Schernthaner G, et al. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005 Apr; 22 (4): 399-405
26. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer Study. J Am Coll Cardiol 2005 Jun 21; 45 (12): 1925-31
27. Tan MH, Johns D, Strand J, et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med 2004 Aug; 21 (8): 859-66
28. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 May 12; 48: 1093-104
29. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000 Dec; 22 (12): 1395-409
30. Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21 (2): 167-74
31. Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004 Feb; 63 (2): 127-34
32. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005 May; 27 (5): 554-67
33. Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002 May; 56 (4): 251-7
34. Derosa G, Cicero AFG, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004 May; 26 (5): 744-54
35. Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004 Jan; 27 (1): 141-7
36. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001 Jul; 111 (1): 10-7
37. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366 (9493): 1279-89
38. Van Wijk JP, De Koning EJ, Martens EP, et al. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003 Oct 1; 23 (10): 1744-9
39. Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure [letter]. Am J Gastroenterol 2002 Feb; 97 (2): 502-3
40. Maeda K. Hepatocellular injury in a patient receiving pioglitazone [letter]. Ann Intern Med 2001 Aug 21; 135 (4): 306
41. May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002 Mar 19; 136 (6): 449-52
42. Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated with pioglitazone. BMJ 2004 Aug 21; 329 (7463): 429
43. Nagasaka S, Abe T, Kawakami A, et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet Med 2002 Apr; 19 (4): 347-8
44. Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 2004 Sep; 38 (9): 1419-23
45. Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med 2005 Aug; 22 (8): 973-9